Compare BANX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANX | TNXP |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.5M | 199.7M |
| IPO Year | 2013 | 2008 |
| Metric | BANX | TNXP |
|---|---|---|
| Price | $21.00 | $11.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.7K | ★ 413.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $18.45 | $9.40 |
| 52 Week High | $23.67 | $29.19 |
| Indicator | BANX | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 38.76 |
| Support Level | $21.01 | $9.72 |
| Resistance Level | $21.29 | $13.36 |
| Average True Range (ATR) | 0.26 | 0.73 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 75.53 | 4.81 |
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.